Phase III trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8)

Creative Commons License

ÖZGÜROĞLU M., Levy B., Horinouchi H., Yu J., Grainger E., Phuong P., ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.33, sa.7, 2022 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 33 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.annonc.2022.07.1097
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
  • İstanbul Üniversitesi Adresli: Hayır